We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test May Replace ELISA for Detecting Antibodies

By LabMedica International staff writers
Posted on 15 Apr 2019
Print article
Image: Dr. Brian Geiss displays a gold microwire that is one-fourth the size of a human hair (Photo courtesy of John Eisele, Colorado State University Photography).
Image: Dr. Brian Geiss displays a gold microwire that is one-fourth the size of a human hair (Photo courtesy of John Eisele, Colorado State University Photography).
A microwire-based test may replace enzyme-linked immunosorbent assay (ELISA) as the primary method to detect antibodies specific for pathogenic microorganisms in patient's sera.

Detection of viral infection is commonly performed using serological techniques like ELISA to detect antibody responses. Such assays may also be used to determine the infection phase based on isotype (IgG or IgM) prevalence. However, ELISAs demonstrate limited sensitivity and are difficult to perform at the point of care.

Investigators at Colorado State University (Fort Collins, USA) have described a method for detecting antibodies against pathogenic viruses with sensitivity significantly better than ELISA. Their method reportedly enables label-free, rapid detection of ultra-low concentrations of virus specific antibodies.

The simple test comprised a capacitive biosensor that incorporated gold microwires coated with Zika or Chikungunya virus envelope antigen. An electrical current passed through the wire created a charge on the wire. Antibodies from the patient's sample bound to the viral proteins on the wire, which increased the outside mass. In addition, antibody binding increased the ability of the wire to hold the charge. By measuring the change in mass, it was possible to quantify the number of antibodies on the surface of the wire.

The investigators reported that with little discernable nonspecific binding, the sensor could detect as few as 10 antibody molecules in a small volume (30 microliters) of fluid within a few minutes. It could also be used to rapidly, specifically, and accurately determine the isotype of antigen-specific antibodies.

"This type of research project is something that none of us could do on our own," said senior author Dr. Brian Geiss, associate professor of microbiology, immunology, and pathology at Colorado State University. "We synergized our efforts to come up with new solutions to problems we are hoping will eventually be used in clinical settings. We hope that it can be used for point-of-care diagnostics, and that it can be developed into a compact hand-held system that can be used in the clinic or in resource-limited areas."

The microwire antibody detection method was described in the April 15, 2019, issue of the journal Biosensors and Bioelectronics.

Related Links:
Colorado State University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.